This raises a question if dose reduction ... of either apixaban or rivaroxaban for extended management of blood clots, noting this was a "weak recommendation" with "very low certainty evidence." ...

To the Editor: Inhibition of factor XI or activated factor XI (XIa) should provide protection against stroke with a low risk of bleeding, given that the incidence of bleeding or adverse ...

for stroke prevention in low-risk patients (CHA2DS2-VASc score of 0–1). Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination ...

The researchers found that apixaban ... low to moderate. "Our findings are similar to those reported by a previous network meta-analysis, which found indirect evidence that therapeutic-dose ...